Search 

ORIGIMM is a young, ambitious Austrian biotech company striving to become a market leader in the treatment of acute and chronic infectious diseases, and dermatological conditions associated with various pathogens.

ORIGIMM is developing the worldwide first therapeutic vaccine for treatment of acne vulgaris; the disease with enormous market potential, afflicting 85% of teenagers and more than 20% of adults below 40 years of age.

Using its proprietary ProVaDis® technology platform ORIGIMM overcomes the challenges in vaccine and immune therapy development by early focus on protective efficacy of antigens in the context of human disease. This translates into a rapid selection of best, most protective candidates with a significantly improved success in clinical trials. ProVaDis platform enables ORIGIMM to rapidly build its product portfolio in many other lucrative areas.

Orphagen’s focus is small molecule discovery at novel drug targets. We create programs leading to first-in-class drugs. Our goal is to partner these with development stage pharmaceutical companies.

We have been first mover in creating three discovery programs for novel targets, including one program that initiated Phase 1 clinical trials with a strategic partner (JT Pharma) in 2013 for autoimmune disease.

We work with novel drug targets from a very productive target class, the nuclear receptors.

Our work has so far been funded by $15 M in federal grants and partnership revenue. Orphagen is in the process of raising equity funding to accelerate current programs.

Orphagen’s lead internal program is for retinitis pigmentosa, the major form of hereditary blindness. Closely following are antagonists to SF-1, a promising target for treatment of Cushing’s syndrome, a life-threatening endocrine disorder, and two cancers with an endocrine connection: prostate cancer and adrenocortical cancer. New target screening may lead to first-in-class programs for glioblastoma, sickle cell anemia, and cancer immunotherapy.

Pappas Ventures is a Venture Capital company based in Durham North Carolina founded in 1994. The firm manages 4 funds for a total of approximately $35 million in assets under management. The firms is currently investing out of its $1 million 4th fund focused exclusively on the life sciences. The firm looks to provide up to $5 million of preferred equity capital in the initial round and up to $1 million over the life of the investment. The firm is very flexible in terms of period to exit but generally looks to exit in around 5 years. The firm plans to make 2-3 investments over the next 6-9 months and will consider companies throughout North America.

PATH is an international nonprofit global health organization that was founded in 1977 and is headquartered in Seattle with 12+ employees in more than 3 offices around the world. PATH is one of the largest nonprofit organizations in global health today. PATH works on a wide array of emerging and persistent global health issues in the areas of health technologies maternal health child health reproductive health vaccines and immunization and emerging and epidemic diseases such as HIV malaria and tuberculosis. PATH is best known for developing and adapting technologies such as improved vaccination devices and new tools to prevent cervical cancer to address the health needs of developing countries. It targets health problems evaluates possible solutions and assesses whether they would be useful in finding health solutions.

PBM Capital is a hybrid family office and operating company based in Charlottesville Virginia with an additional office in New York City. The firm is funded and led by the successful life science entrepreneur Paul Manning who started and sold several companies in his career. The firm can make investments ranging from approximately $5 to $1 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity controlling interest in-licensing MBO/LBO growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.